Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3858279 in chronic diabetic peripheral neuropathic pain
NCT05838755Phase 2Terminated
- Sponsor
- GSK
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of GSK3858279 in diabetic polyneuropathy (DPN) (3 arms), sponsored by GSK. Primary endpoint: Change From Baseline in the Weekly Average of Average Daily Pain Score at Week 12, Assessed on the Numeric Rating Scale. Started Sep 2023; status: terminated.
02
Drugs
GSK3858279
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05838755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838755.